Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Austedo
Pharma
Neurocrine's Ingrezza guidance spooks investors
Neurocrine's stock price took a tumble Friday after the company revealed its 2025 revenue forecast for its tardive dyskinesia med Ingrezza.
Zoey Becker
Feb 10, 2025 9:13am
Teva's subdued outlook puts damper on strong 2024 results
Jan 29, 2025 1:13pm
Teva looks to peel back the onion on mental health: exec
Dec 31, 2024 8:00am
Hefty sales of generics boost Teva to another big quarter
Nov 6, 2024 3:19pm
Teva rides growth momentum through Q2, boosts '24 sales outlook
Jul 31, 2024 9:11am
Teva CEO celebrates progress in 'Pivot to Growth' plan
May 8, 2024 3:02pm
